Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines.
Recombinant measles virus (rMV) vectors expressing heterologous viral membrane protein antigens are potentially useful as vaccines. Genes encoding the mumps virus haemagglutinin-neuraminidase (MuV-HN), the influenza virus haemagglutinin (Flu-HA) or the respiratory syncytial virus fusion (RSV-F) proteins were inserted into the genome of a live attenuated vaccine strain of measles virus. Additionally, in this case rMV with the MuV-HN or the influenza HA inserts, chimeric constructs were created that harboured the measles virus native haemagglutinin or fusion protein cytoplasmic domains. In all three cases, sucrose-gradient purified preparations of rMV were found to have incorporated the heterologous viral membrane protein on the viral membrane. The possible utility of rMV expressing RSV-F (rMV.RSV-F) as a vaccine was tested in a cotton rat challenge model. Vaccination with rMV.RSV-F efficiently induced neutralizing antibodies against RSV and protected animals from infection with RSV in the lungs.
Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Cindy
C
Swett-Tapia
Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Lies
L
Bogaert
Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Pascal
P
de Jong
Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Vladimir
V
van Hoek
Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Theo
T
Schouten
Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Irma
I
Damen
Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Dirk
D
Spek
Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Patrick
P
Wanningen
Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Katarina
K
Radošević
Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Myra N
MN
Widjojoatmodjo
Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Roland
R
Zahn
Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Jerome
J
Custers
Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
Soumitra
S
Roy
D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D004195:Disease Models, Animal; D004337:Drug Carriers; D005822:Genetic Vectors; D008168:Lung / Q000276:immunology / Q000821:virology; D008459:Measles virus / Q000235:genetics*; D011817:Rabbits; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D012136:Respiratory Syncytial Viruses / Q000235:genetics / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014763:Viral Matrix Proteins / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D004337:Drug Carriers; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014763:Viral Matrix Proteins; D014765:Viral Vaccines